HCIT & Life Sciences

We, at AGC, see great promise and market activity in HCIT and Life Sciences technology, having represented venture backed companies to entrepreneurs in their exits with many of the leading acquirers, as well as helping to raise capital to continue our clients’ growth trajectories. A core thesis that we continue to applaud is the intersection of trends in HCIT and Life Sciences technology.  These intersecting technologies not only allow providers to understand patients better, but can also deliver customized experiences in addition to elevating health care engagement.  Building and nurturing technology relationships with patients requires a mindset change not only in HCIT but in Life Sciences.  HCIT and Life Sciences companies are already starting to establish a solid foundation of patient data and using data analytics to understand and address gaps in care.  Life Sciences companies realize that technology is the driving force not only for how they develop therapies, but also for how they go to market, how they collaborate with payers and providers, and engage with their patients. These trends are giving rise to Precision Medicine, through the use of genomics and other technologies such as remote patient monitoring, which is at the intersection of HCIT and Life Sciences technology.

View More Transactions

Sector Team

See our Insights on the Industry and its Sectors


See What Clients Have To Say...

Client Testimonial: It was a pleasure to have AGC on our Team. AGC was passionate about working with us in our review of alternatives that culminated in a successful minority investment by both a strategic FinTech and venture investor and existing investors participating. They were with us 24/7 with intense focus on every detail and proven knowledge of companies and deals like ours. We look forward to continuing to work with AGC. Vijay Sikka, Founder & CEO, Sikka Software

AGC Partners acted as sole financial advisor to Sikka Software in August, 2019

Client Testimonial: We worked with Tristan, Mike, and the AGC team through an intensive process of preparing our materials and engaging with potential transaction partners. They provided expert service and guidance, and the networking of Tristan and Mike with key industry players was instrumental. AGC pushed incredibly hard to deliver a great outcome. Ben Glick, Founder, President & Chief Scientist, SnapGene

AGC Partners acted as sole financial advisor to SnapGene in August, 2019

Client Testimonial: Throughout Bernoulli's acquisition process—one that is to be critical in supporting and enabling the Company's next phase of growth—we knew we needed a financial advisor that would act as a true business partner. We wanted a team that would help guide us through meetings and narrow down the investor field, while still allowing us to make the decisions that were best for Bernoulli. We chose Hugh Hoffman and AGC Partners because of their expertise in the HCIT sector of the technology industry and like-minded dedication to maintaining Bernoulli's core business values. With the support of AGC Partners, Bernoulli was able to secure a terrific outcome for our investors, shareholders, customers and employees. Janet Dillione, CEO, Bernoulli

AGC Partners acted as sole financial advisor to Bernoulli in April, 2019